AB-506 presentation | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

  • Important Upgrade Notice: 

    At 9 pm Central, Sunday 2/16/2020, we launched the following tools as Phase One of our Premium Plus service (full service package still under development): 

    1) Customizable Scrolling Ticker
    2) Portfolio Manager
    3) Stock-specific News & Trading Email Alert Notifications

    These products are immediately available to Precious Metal & Gemstone Patrons. 

    To watch a tutorial on the "regular" site, click here. On "premium," click here

ABUS   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34754 of 34763  at  1/10/2020 11:34:20 AM  by

The Rooster

AB-506 presentation

 The AB-506 capsid inhibitor discontinuation presentation is on the Arbutus website.  It does seem like it was working pretty good (more than 200-fold decreases in HBV RNA and DNA).  But in the small sample size, Arbutus seems to be suggesting that Asian subjects were suffering ALT increases (i.e., liver toxicity) that were not seen in Caucasian subjects.  They conclude they remain committed to developing a next generation capsid inhibitor which could be very frightening to some investors.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 275
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
34755 Re: AB-506 presentation spaddy 1 1/13/2020 9:21:23 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by